A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis

Tissue Antigens

Volumn 69, Issue 3, 2007, Pages 227-235

  Agarwal, K ^a   Czaja, A J ^b   Donaldson, P T ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b MAYO CLINIC   (United States)

Author keywords

Apoptosis; Autoimmunity; Complex disease; Fas; Genetics; Immune regulation; Polymerase chain reaction; TNFRSF6; Type 1 autoimmune hepatitis

Indexed keywords

ADENOSINE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; FAS ANTIGEN; GUANINE; HLA ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PREDNISONE;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOME; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT FAILURE; TREATMENT OUTCOME;

ALLELES; ANTIGENS, CD95; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS);

EID: 34247882930     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2006.00794.x     Document Type: Article

References (65)

1. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998 : 33 : 99 103.
2. Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991 : 13 : 701 6.
3. Strettell MDJ, Donaldson PT, Thompson LJ et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997 : 112 : 2028 35.
4. Doherty DG, Donaldson PT, Underhill JA et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 1994 : 19 : 609 15.
5. Donaldson PT, Manns MP. Immunogenetics of liver disease. In : Bircher J, Benhamou J-P, McIntyre N, Rizzetto M, Rhodes J, eds. Oxford Textbook of Clinical Hepatology, Vol. 1 Oxford University Press, Oxford, 1999, 173-88.
6. Becker KG, Simon RM, Bailey-Wilson JE et al. Clustering of non-major histocompatibility complex susceptibility loci in human autoimmune diseases. Proc Natl Acad Sci USA 1998 : 95 : 9979 84.
7. Becker KG. Comparative genetics of type 1 diabetes and autoimmune disease. Diabetes 1999 : 48 : 1353 8.
8. Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000 : 174 : 250 9.
9. Donaldson PT. Genetics of autoimmune hepatitis. Semin Liver Dis 2002 : 22 : 353 63.
10. Cookson S, Constantini PK, Clare M et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999 : 30 : 851 6.
11. Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 1999 : 117 : 645 52.
12. Agarwal K, Czaja AJ, Jones DEJ, Donaldson PT. CTLA-4 polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000 : 31 : 49 53.
13. Chervonsky AV. Apoptotic and effector pathways in autoimmunity. Curr Opin Immunol 1999 : 11 : 684 8.
14. Hugot J-P, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001 : 411 : 599 603.
15. Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001 : 411 : 603 6.
16. Todd JA. Tackling common disease. Nature 2001 : 411 : 537 9.
17. Hampe J, Cuthbert A, Croucher PJP et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001 : 357 : 1925 8.
18. Nagata S. Apoptosis by death factor. Cell 1997 : 88 : 355 65.
19. Fox CK, Furtwaengler A, Nepomuceno RR, Martinez OM, Krams SM. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver 2001 : 21 : 272 9.
20. Wen L, Peakman M, Lobo-Yeo A et al. T-cell directed hepatocyte damage in autoimmune chronic active hepatitis. Lancet 1990 : 336 : 1527 30.
21. Lohr H, Manns M, Kyriatsoulis A et al. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol 1991 : 84 : 297 302.
22. Lohr HF, Schaak JF, Gergen G, Fleischer B, Dienes H-P, Meyer zum Buschenfelde K-H. Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients with chronic active hepatitis of different etiology. Liver 1994 : 14 : 161 6.
23. Ogawa S, Sakaguchi K, Takaki A et al. Increase in CD95 (Fas/APO-1)-positive CD4+ and CD8+ T cells in peripheral blood derived from patients with autoimmune hepatitis or chronic hepatitis C with autoimmune phenomena. J Gastroenterol Hepatol 2000 : 15 : 69 75.
24. Cheng J, Liu C, Koopman WJ, Mountz JD. Characterisation of human Fas gene - exon/intron organisation and promotor region. J Immunol 1995 : 154 : 1239 45.
25. Huang QR, Morris D, Manolios N. Identification and characterisation of polymorphisms in the promoter region of human Apo-1/Fas (CD95) gene. Mol Immunol 1997 : 34 : 577 82.
26. Huang QR, Danis V, Lassere M, Edmonds J, Manolinos N. Evaluation of a new apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology 1999 : 38 : 645 51.
27. Huang QR, Teutsch SM, Buhler MM et al. Evaluation of the apo-1/Fas promoter mvaI polymorphism in multiple sclerosis. Mult Scler 2000 : 6 : 14 8.
28. Hiraide A, Imazeki F, Yokosuka O et al. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol 2005 : 100 : 1322 9.
29. Sun T, Zhou Y, Li H et al. FASL-844C polymorphism is associated with increased activation-induced cell death and risk of cervical cancer. J Exp Med 2005 : 202 : 967 74.
30. Mehrian R, Quismorio FP Jr., Strassmann G et al. Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 1998 : 41 : 596 602.
31. Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999 : 31 : 929 38.
32. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992 : 103 : 1290 5.
33. Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983 : 85 : 713 7.
34. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 1993 : 18 : 816 822.
35. Czaja AJ, Homburger HA. Autoantibodies in liver disease. Gastroenterology 2001 : 120 : 239 49.
36. Homburger HA, Cahen YD, Griffiths J, Jacob GL. Detection of antinuclear antibodies. Comparative evaluation of enzyme immunoassay and indirect immunofluorescence methods. Arch Pathol Lab Med 1998 : 122 : 993 9.
37. Summerskill WHJ, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975 : 16 : 876 83.
38. Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993 : 105 : 1824 32.
39. Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 2004 : 39 : 1631 38.
40. Czaja AJ, Beaver SJ, Shiels MT. Sustained remission following corticosteroid therapy of severe HBsAg-negative chronic active hepatitis. Gastroenterology 1987 : 92 : 215 9.
41. Czaja AJ, Menon KVN, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002 : 35 : 890 7.
42. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004 : 40 : 644 50.
43. Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis 2002 : 6 : 727 37.
44. Lenardo M, Chan FK, Hornung F et al. Mature T lymphocyte apoptosis- immune regulation in a dynamic and unpredicatble antigenic environment. Annu Rev Immunol 1999 : 17 : 221 53.
45. Siegel RM, Chan FK-M, Chun HJ, Lenardo MJ. The multifaceted role of Fas signalling in immune cell homeostasis and autoimmunity. Nat Immunol 2000 : 1 : 469 75.
46. Ogasawara J, Watanabe-Fukunaga M, Adachi M et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993 : 364 : 806 9.
47. Patel T, Steer CJ, Gores GJ. Apoptosis and the liver: a mechanism of disease, growth regulation, and carcinogenesis. Hepatology 1999 : 30 : 811 5.
48. Rust C, Gores GJ. Apoptosis and liver disease. Am J Med 2000 : 108 : 567 74.
49. Natori S, Rust C, Stadheim LM, Srinivasan A, Burgart LJ, Gores GJ. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol 2001 : 34 : 248 53.
50. Pinkoski MJ, Brunner T, Green DR, Lin T. Fas and Fas ligand in the gut and liver. Am J Physiol 2000 : 278 : 354 66.
51. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997 : 3 : 409 13.
52. Klugewitz K, Blumenthal-Barby F, Schrage A, Knolle PA, Hamann A, Crispe IN. Immunomodulatory effects of the liver: deletion of activated CD4 effector cells and suppression of interferon-gamma producing cells after intravenous protein immunisation. J Immunol 2002 : 169 : 2407 13.
53. Park S, Murray D, John B, Crispe IN. Biology and significance of T cell apoptosis in the liver. Immunol Cell Biol 2001 : 80 : 74 83.
54. Kanemitsu S, Ihara K, Saifddin A et al. A functional polymorphism in Fas (CD95/Apo-1) gene promoter associated with SLE. J Rheumatol 2002 : 29 : 1183 8.
55. Iredale JP, Benyon RC, Pickering J et al. Mechanisms of spontaneous resolution of rat liver fibrosis: hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998 : 102 : 538 49.
56. Issa R, Williams E, Trim N et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 2001 : 48 : 548 57.
57. Murphy FR, Issa R, Zhou X et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002 : 277 : 11069 76.
58. Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated HBsAg-negative chronic active hepatitis. Gastroenterology 1984 : 87 : 1222 7.
59. Roberts SK, Therneau T, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996 : 110 : 848 57.
60. Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediatr 1967 : 70 : 891 9.
61. Vaishnaw AK, Toubi E, Ohsako S et al. The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/Apo-1) mutations. Arthritis Rheum 1999 : 42 : 1833 42.
62. Jackson CE, Fischer RE, Hsu AP et al. ALPS with a defective Fas genotype: influence on penetrance. Am J Hum Genet 1999 : 64 : 1002 14.
63. Rosen A, Casicola-Rosen L. Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Diff 1999 : 6 : 6 12.
64. Coakley G, Manolios N, Loughran TP Jr., Panayi GS, Lanchbury JS. A Fas promoter polymorphism at position -670 in the enhancer region does not confer susceptibility to Felty's and large granular lymphocyte syndromes. Rheumatology 1999 : 38 : 883 6.
65. Nolsoe RL, Kristiansen OP, Sangthongpitag K et al. Complete molecular scanning of the human Fas gene: mutational analysis and linkage studies in families with type 1 diabetes mellitus. Diabetologia 2000 : 43 : 800 8.